<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376868</url>
  </required_header>
  <id_info>
    <org_study_id>MaestroAPII</org_study_id>
    <nct_id>NCT02376868</nct_id>
  </id_info>
  <brief_title>Maestro Agreement and Precision Study II</brief_title>
  <official_title>Topcon 3D OCT-1 Maestro Agreement and Precision Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber
      Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the
      Maestro and iVue OCT devices.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic Disc Measurements (Optic Disc/Cup Size)</measure>
    <time_frame>1 Hour</time_frame>
    <description>Reporting of the Optic Disc Size and Cup Size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) Thickness Measurements At Different Clock Hours</measure>
    <time_frame>1 Hour</time_frame>
    <description>RNFL thickness measured at different clock hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full Retinal Thickness Measurements</measure>
    <time_frame>1 Hour</time_frame>
    <description>Full Retinal Thicknesses measured in different quadrants of the scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ganglion Cell Thickness Measurements</measure>
    <time_frame>1 Hour</time_frame>
    <description>Ganglion Cell Thickness measured in different quadrants of the scan</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Normal Healthy Subjects With No Known Ocular Diseases</condition>
  <condition>Glaucomatous Eyes</condition>
  <condition>Eyes With Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D OCT-1 Maestro</intervention_name>
    <description>OCT machines used for diagnostic purposes</description>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iVue</intervention_name>
    <description>OCT machines used for diagnostic purposes</description>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. lOP &lt;=21 mmHg bilaterally

          5. BCVA 20/40 or better (each eye)

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses&gt; 20% or false positives&gt;
             33%, or false negatives&gt; 33%

          5. Visual field defects consistent with glaucomatous optic nerve damage with at least one
             of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1 of
                  which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          6. Presence of any ocular pathology except for cataract

          7. Narrow angle

          8. History of leukemia, dementia or multiple sclerosis

          9. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. BCVA 20/40 or better in the study eye

          4. Visual field defects consistent with glaucomatous optic nerve damage based on with at
             least one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1 of
                  which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or
             retinal nerve fiber layer structural abnormalities:

               1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially
                  at the inferior or superior poles with or without disc hemorrhage;

               2. Localized abnormalities of the peripapillary retinal nerve fiber layer,
                  especially at the inferior or superior poles; or

               3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural
                  tissue

        Exclusion Criteria for Glaucoma Group

          1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as
             fixation losses&gt; 20% or false positives&gt; 33%, or false negatives &gt; 33% in the study
             eye

          5. Presence of any ocular pathology except glaucoma in the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retina Disease Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. lOP&lt;= 21 mmHg in the study eye

          5. BCVA 20/400 or better in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Disease Group

          1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye

          5. Narrow angle in the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Reisman, MS</last_name>
    <role>Study Director</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

